Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 14/20 | 0.54 |
| ▸ | KDM1A | O60341 | 1/20 | 0.51 |
| ▸ | AMY1A | P0DUB6 | 4/20 | 0.48 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.47 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10085683 | 1.00 | HSD11B1 (0.54) | HSD11B1KDM1AAMY1ATRPC3TRPC6 | |
| SCHEMBL525297 | 0.90 | HSD11B1 (0.54) | HSD11B1 | |
| SCHEMBL10086347 | 0.90 | HSD11B1 (0.54) | HSD11B1 | |
| SCHEMBL10086313 | 0.89 | HSD11B1 (0.47) | HSD11B1 | |
| SCHEMBL524954 | 0.89 | HSD11B1 (0.47) | HSD11B1 | |
| SCHEMBL525422 | 0.89 | HSD11B1 (0.48) | HSD11B1 | |
| SCHEMBL10085602 | 0.89 | HSD11B1 (0.48) | HSD11B1 | |
| SCHEMBL10085605 | 0.87 | HSD11B1 (0.56) | HSD11B1AMY1ATRPC3TRPC6 | |
| SCHEMBL525620 | 0.87 | HSD11B1 (0.56) | HSD11B1AMY1ATRPC3TRPC6 | |
| SCHEMBL525749 | 0.87 | HSD11B1 (0.56) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120029029-A1 | SUBSTITUTED THIAZOL-2-YLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS 11-BETA HSD1 MODULATORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-02-02 | — | — | US | claimed |
| US-20120029029-A1 | SUBSTITUTED THIAZOL-2-YLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS 11-BETA HSD1 MODULATORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029029-A1 | SUBSTITUTED THIAZOL-2-YLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS 11-BETA HSD1 MODULATORS | HSD11B1, HSD11B2, HSD3B1 | HSD11B1 1/4885KDM1A 2509/4885AMY1A 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.